Back to search results

Emapalumab to Prevent Side Effects from Bispecific Antibody Therapy

This study is testing if a drug called emapalumab can prevent serious side effects like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in people receiving bispecific antibody therapy for certain blood cancers. You may be eligible if you are an adult (18 or older) with large B-cell lymphoma or multiple myeloma that has come back or hasn't responded to other treatments. The study will look at how many participants experience these side effects within 30 days of receiving the bispecific antibody. The goal is to see if emapalumab is effective and safe. The study plans to enroll 60 participants, but its current status is unclear.

Study design
This is an interventional study planning to enroll 60 participants. It is testing emapalumab given one day before bispecific antibody therapy.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary side effects will be measured within 30 days of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07567014

Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS

Not Yet Recruiting
PHASE2Ages 18+InterventionalPrevention
NYU Langone Health
~60 participants
Updated 2026-05-06 on ClinicalTrials.gov
What's tested:Emapalumab

At a glance

Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with cytokine release syndrome (CRS) (grades 2-5, as per ASTCT criteria) and/or immune effector cell-associated neurotoxicity syndrome (ICANS) (grades 2-5, per ASTCT criteria) within 30 days of bispecific antibody administration.
Measured over Within 30 days of treatment

Conditions

Multiple Myeloma
Large B-cell Lymphoma (LBCL)

Explore related trials

Large B-cell lymphomaMultiple Myeloma

Where it's being run

3 sites across 1 states
New York3

Study leadership

  • Oscar B. Lahoud, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Health

Who to contact

Oscar B. Lahoud, MD
[email protected]
646-754-8570
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diffuse large B-cell lymphoma (DLBCL) not otherwise specified,
Primary mediastinal large B-cell lymphoma,
High-grade B-cell lymphoma,
DLBCL arising from follicular lymphoma. 2. Adult patients with R/R multiple myeloma (MM) who have received multiple lines of therapy and are planned to receive a commercially approved bispecific antibody therapy. These prior therapies will typically include a proteasome inhibitor (e.g., bortezomib, carfilzomib), an immunomodulatory drug (e.g., lenalidomide, pomalidomide), and an anti-CD38 monoclonal antibody (e.g., daratumumab). 2. Treatment Eligibility:

What this trial measures

  • Number of participants with cytokine release syndrome (CRS) (grades 2-5, as per ASTCT criteria) and/or immune effector cell-associated neurotoxicity syndrome (ICANS) (grades 2-5, per ASTCT criteria) within 30 days of bispecific antibody administration.Within 30 days of treatment